Table 1 Study population characteristics
| Â | Mean | (Minimum/maximum) |
|---|---|---|
Age (years) | 43 ± 0.45 | (18–74) |
Weight (kg) | 110.7 ± 0.8 | (65.8–226.6) |
Height (m) | 1.68 ± 0.003 | (1.47–2.06) |
BMI (kg/m2) | 38.8 ± 0.22 | (24.97–69.13) |
Waist circumference (cm) | 116.7 ± 0.5 | (83.5–193) |
Hip circumference (cm) | 122.2 ± 0.4 | (95–160) |
Waist-to-hip ratio | 0.96 ± 0.004 | (0.66–1.35) |
Fat free mass (kg) | 56.2 ± 0.4 | (36.5–110) |
Fat mass (kg) | 54.3 ± 0.5 | (16.9–134.5) |
Fat mass (%) | 48.87 ± 0.27 | (22.3–65.3) |
Total abdominal adipose tissue (cm2) | 799.5 ± 6.6 | (246–1386) |
Visceral abdominal tissue (cm2) | 195.9 ± 3.2 | (29–567) |
Subcutaneous abdominal tissue (cm2) | 603.6 ± 5.6 | (166–1059) |
Systolic blood pressure (mmHg) | 127.1 ± 0.5 | (90–180) |
Diastolic blood pressure (mmHg) | 75.45 ± 0.37 | (49–115) |
Creatinine kinase (mg/dL) | 0.81 ± 0.006 | (0.38–1.64) |
Aspartate aminotransferase (U/L) | 23.6 ± 0.5 | (7–133) |
Alanine aminotransferase (U/L) | 35.8 ± 0.8 | (7–265) |
Alkaline phosphatase (U/L) | 79.94 ± 0.79 | (30–236.03) |
gamma-glutamyltransferase (U/L) | 43.43 ± 1.19 | (11.79–315.16) |
Total cholesterol (mg/dL) | 199 ± 1.40 | (75–400.44) |
High-density-lipoprotein Cholesterol (mg/dL) | 50.83 ± 0.49 | (24–107.17) |
Triglycerides (mg/dL) | 152.97 ± 2.93 | (17–823.01) |
Low-density-lipoprotein cholesterol (mg/dL) | 117.81 ± 1.24 | (17.6–294.76) |
Insulin resistance (HOMA) | 4.27 ± 0.23 | (0.07–147.65) |
Steatosis (0:1:2:3) | 109:151:119:82 | Â |
Ballooning (0:1:2) | 139:187:135 | Â |
Lobular inflammation (0:1:2:3) | 148:208:75:30 | Â |
Fibrosis stage (0:1:2:3:4) | 287:91:51:28:3 | Â |
Adjusted SAF activity (0:1:2:3:4:5) | 100:71:112:118:44:16 | Â |
NAFLD activity score (0:1:2:3:4:5:6:7:8) | 75:44:48:62:84:60:50:30:8 | Â |
NAFLD staging (1:2:3:4) | 61:80:210:53 | Â |